Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study

BACKGROUND: Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use. An efficacious, tolerable, and convenient PI option is needed. METHODS: In this single‐cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Man, Zhang, Jiajia, Tang, Ran, Wang, Yuhao, Zhan, Xiaokai, Fan, Sibin, Huang, Zhongxia, Zhong, Yuping, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160809/
https://www.ncbi.nlm.nih.gov/pubmed/34655168
http://dx.doi.org/10.1002/cam4.4313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160809/
https://www.ncbi.nlm.nih.gov/pubmed/34655168
http://dx.doi.org/10.1002/cam4.4313

Ejemplares similares